Home > Insider Trading > Filing (0001127602-19-027930)

Filing Details

Accession Number:: 0001127602-19-027930
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-09-04 18:07:11
Reporting Period:: 2019-08-30

Accepted Time:: 2019-09-04 18:07:11
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
318154	Amgen Inc	AMGN	Biological Products, (No Disgnostic Substances) (2836)	953540776

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1560565	M Cynthia Patton	One Amgen Center Drive Thousand Oaks CA 91320-1799	Svp & Cco	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2019-08-30	5,749	$156.35	32,648	No	4	M	Direct
Common Stock	Disposition	2019-08-30	5,749	$208.07	26,899	No	4	S	Direct
Common Stock	Acquisiton	2019-08-30	2,875	$162.60	29,774	No	4	M	Direct
Common Stock	Disposition	2019-08-30	2,875	$208.07	26,899	No	4	S	Direct
Common Stock	Disposition	2019-08-30	4,802	$208.07	22,097	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Nqso (Right to Buy)	Disposition	2019-08-30	5,749	$0.00	5,749	$156.35
Common Stock	Nqso (Right to Buy)	Disposition	2019-08-30	2,875	$0.00	2,875	$162.60

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
2,962	2018-05-03	2026-05-03	No	4	M	Direct
5,839	2019-05-01	2027-05-01	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	264	Indirect	401(k) Plan

Footnotes

The price reported is an average price. The prices ranged from $207.425 to $208.520 per share for this cashless exercise of 5,749 stock options expiring May 3, 2026. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.
The price reported is an average price. The prices ranged from $207.425 to $208.520 per share for this cashless exercise of 2,875 stock options expiring May 1, 2027. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.
The price reported is an average price. The prices ranged from $207.425 to $208.520 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.
These shares include the following RSUs granted under the Company's equity plans: 348 RSUs which vest on 5/3/2020; 660 RSUs which vest in installments of 325 on 5/1/2020 and 335 on 5/1/2021; 901 RSUs which vest in installments of 297 on 4/27/2020, 297 on 4/27/2021 and 307 on 4/27/2022; and 902 RSUs which will vest in installments of 297 on 5/3/2021, 298 on 5/3/2022 and 307 on 5/3/2023. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
These shares include 116 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
These are shares acquired under the Company's 401(k) Plan and represent interests in the Company's stock fund as of this filing.